DIRS.INFO The most relevant business & tech news

☆ We're repurchasing shares of a health-care stock that we recently sold much higher
▼ + stars: | 2024-11-22 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

We are buying 50 shares of GE Healthcare at roughly $81.51. Following the trade, Jim Cramer's Charitable Trust will own 975 shares of GEHC, increasing its weighting to 2.2% from about 2.1%. GE Healthcare may be best known for selling medical equipment like MRI and CT machines, but its pharmaceutical diagnostics business is what's most exciting right now. One more thing we liked was GE Healthcare commitment to expand its adjusted EBIT margins. This year, GE Healthcare expects its adjusted EBIT margin to be between 15.8% and 16%.

Persons: Jim Cramer's, Vizamyl, We've, Donald Trump, Jim Cramer, Jim Organizations: GE Healthcare, GEHC, GE, CNBC Locations: China

☆ GE Healthcare has been an under-the-radar winner — and a new catalyst just arrived
▼ + stars: | 2024-09-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

Wall Street currently sees GE Healthcare earning $6.72 per share in 2028, according to FactSet, up from $4.25 projected this year. GE Healthcare has been a stock we've been battling since its steep slide during the second quarter. That dynamic — coupled with the positive China stimulus announcements in recent days — turned GE Healthcare into one of our top-performing stocks in the third quarter . A PET scan using Flyrcado has better diagnostic efficacy than SPECT scans, according to GE Healthcare. GE Healthcare may also see a recovery in its China business due to the roll out of medical-focused stimulus spending .

Persons: Wells, Flyrcado —, Wells Fargo, Flyrcado, FactSet, Jim Cramer, —, Jim, Leqembi, Eli Lilly, Stifel, Jim Cramer's, Yi Haifei Organizations: GE Healthcare, GE, Food and Drug Administration, Wall, FDA, Federal, Club, CDC, Management, CNBC, Fair for Trade, Services, China National Convention Center, China News Service, Getty Locations: China, U.S, Beijing

☆ Tuesday's analyst calls: Taiwan Semiconductor a buying opportunity, CrowdStrike upgraded
▼ + stars: | 2024-08-06 | by ( Fred Imbert | ) www.cnbc.com time to read: +6 min

He increased his price target by $25 to $575, which suggests shares can jump about 20.9% over the next year. Rollins upgraded the stock to neutral from sell and upped his price target from $1.25 to $3.15 per share, which implies roughly 21.6% potential upside. Analyst Rick Wise initiated coverage of GE Healthcare with a buy rating and $100 price target, which suggests 22.7% upside. Analyst Rob Owens upgraded the global cybersecurity company to overweight from neutral and lowered his price target by $20 to $290, which implies 30.6% upside. Its price target of 1,200 Taiwanese dollars implies upside of 36.4%.

Persons: Morgan Stanley, Piper Sandler, Rob Sanderson, Sanderson, — Pia Singh, Michael Rollins, Rollins, Lumen, Rick Wise, Wise, CrowdStrike, Rob Owens, Owens, pare, Price, Charlie Chan, Chan, Fred Imbert Organizations: CNBC, Taiwan Semiconductor, Meta, Citi, Lumen Technologies, GE Healthcare, Delta Air Lines, Microsoft Locations: U.S

☆ GEHC gives reasons to look beyond temporary China woes and shares reverse higher
▼ + stars: | 2024-07-31 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. Organic revenue growth was 1%. We saw a continued acceleration of Vizamyl doses delivered in the U.S. in the second quarter. This is still a small contributor to sales growth but gives us optimism about its sales potential over the next few years." As a result, we're lowering our total company full-year organic revenue growth guidance."

Persons: Philips, It's, Eli Lilly, GEHC, —, Jay Saccaro, We're, Arduini, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: GE Healthcare, Management, Revenue, LSEG, General Electric, Philips, Siemens, Club, GE Healthcare YTD, GE Healthcare's, Care Solutions, Pharmaceutical Diagnostics, U.S, CNBC, Lightrocket, Getty Locations: China, Eisai, U.S

☆ A successful Alzheimer's drug will help Eli Lilly join the $1 trillion club
▼ + stars: | 2024-06-11 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. The billions of dollars in Eli Lilly is investing in manufacturing capacity support the idea that the long-term opportunity is immense. Adding Eli Lilly to the market could help address some of the obstacles that limited Leqembi's sales early on. Eli Lilly, which has spent billions in search of a successful Alzheimer's treatment , had hoped for donanemab to be approved by now. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana.

Persons: Eli Lilly, donanemab, Eli Lilly's, Donanemab, Leqembi —, Biogen, —, Jim Cramer's, Ken Langone, Morgan Stanley, Cantor Fitzgerald, Leqembi, Jim Cramer, Jim, Scott Olson Organizations: Food and Drug Administration, FactSet, Novo Nordisk, FDA, GE Healthcare, CNBC, Company, Getty Locations: GLP, Indianapolis , Indiana

☆ Apple jumps to a new high after AI unveil — plus, our latest thinking on 6 more portfolio stocks
▼ + stars: | 2024-06-11 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. "Notice where Stanley Black & Decker is when you have a good day for the bonds," Jim Cramer pointed out. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, you'll, Stanley Black, Decker, Dupont, Ed Breen, Jim, Eli Lilly, Eli Lilly Alzheimer's, Banks, Wells, Michael Santomassimo, Santomassimo, Morgan Chittum, We've, Tom Jorden, Coterra, Jorden, Jerome Powell, Jim Cramer's Organizations: CNBC, Longtime, Apple, Treasury, Club, DuPont, GE Healthcare, Huntington, Investing Club, Coterra Energy, Broadcom, VMware, Jim Cramer's Charitable

☆ GE Healthcare's disappointing first quarter offers both a lesson and an opportunity
▼ + stars: | 2024-04-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +10 min

GE Healthcare shares sank Tuesday after the company's first-quarter sales and profits fell slightly short of the Wall Street consensus. GE Healthcare Why we own it : GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions in health care. That's what we have to say about this GE Healthcare quarter. This contributed to some of the softness in the first quarter quarter. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images

Persons: didn't, GE Healthcare's, —, it's, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, LSEG, General Electric, Philips, Siemens, GE Healthcare YTD, GE, Management, Alzheimer's, CNBC, Getty Locations: China, Covid, Jena , Germany

☆ What Eli Lilly investors can learn from the slow launch of a competitor's drug
▼ + stars: | 2024-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. The FDA's decision on Lilly's drug, known as donanemab, is expected by the end of March. In the meantime, Eli Lilly's diabetes and obesity drugs, the heart of our investment thesis, should continue to fuel the lion's share of the company's topline growth. About 2,000 patients are currently taking Leqembi, Biogen said Tuesday, up from 800 at the time of the company's third-quarter report in November. LLY YTD mountain Eli Lilly's stock performance so far in 2024.

Persons: Eli Lilly, drugmaker Biogen, Eli Lilly's, —, Lilly, Biogen, Japan's, Chris Viehbacher, Viehbacher, Morgan Stanley, Lilly's, Donanemab, Mounjaro, Jim Cramer, Leqembi, Jim Cramer's, Jim Organizations: Food and Drug Administration, Drug Administration, Alzheimer's Association, FDA, Club, GE Healthcare, FactSet, Pharmaceutical, CNBC Locations: Indianapolis

☆ Health care has had a tough year. Where we stand on our 5 stocks in the sector
▼ + stars: | 2023-09-22 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +12 min

Bausch Health (BHC) is a different case. Key points Health-care stocks outperformed the broader U.S. stock market last year, but this year it's been much-tougher sledding for the sector due to a variety of headwinds. We feel comfortable owning our three other primary health care stocks: GE Healthcare, Humana and Danaher. In recent weeks, analysts at Wells Fargo and Citigroup have started coverage of GE Healthcare with buy ratings. The analysts at Jefferies now rate Bausch Health stock a buy, with a price target increase to $16 per share from $9.

Persons: There's Eli Lilly, Eli Lilly, That's, Eli Lilly's, Ryan Issakainen, we're, Issakainen, –, Stryker, Jim Cramer, it's, Jim, We've, Bausch, BHC, We're, I'm, Jefferies, Jim Cramer's, Frederick Florin Organizations: GE Healthcare, Health, Federal Reserve, First Trust Advisors, Humana, Medicare, Dow, UnitedHealth, GE, General Electric, —, Citigroup, Jefferies, CNBC, AFP, Getty Locations: what's, China, STE, Biogen, Wells, Bausch, Fegersheim, France

☆ The market scoffs at GE Healthcare's beat and raise, but we see an opening
▼ + stars: | 2023-07-25 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

We first bought up a modest number of GE Healthcare shares in May, while patiently waiting for a retreat in the price. The difference between the two companies suggests to us that GE Healthcare may be taking market share in the industry. General Electric (GE) spun off GE Healthcare at the start of this year. Guidance Off the strength of the first half of the year, GE Healthcare raised its full-year outlook for organic revenue growth and adjusted EPS. Alzheimer's opportunity We continue to see upside for GE Healthcare as it attracts new business to support the launch of nascent Alzheimer's therapies.

Persons: GEHC, It's, Phillips, EBIT, Peter Arduini, Jim Cramer, Jim Cramer's, Jim, Jakub Porzycki Organizations: GE Healthcare Technologies, Alzheimer's, GE Healthcare, Dutch, GE, General Electric, CNBC, Nurphoto, Getty Locations: U.S

☆ The market is undervaluing this stock — so we're adding to our position
▼ + stars: | 2023-07-18 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . A GE Healthcare Ltd. BioProcess machine stands on display during the International Pharmaceutical Expo (Interphex) in New York.

Persons: Jim Cramer's, GEHC, Jim Cramer, Jim Organizations: GE Healthcare Technologies, GEHC, Medicare, GE Healthcare, Alzheimer's, CNBC, GE Healthcare Ltd, International Pharmaceutical, Bloomberg, Getty Locations: New York

We're initiating a position in GE Healthcare (GEHC), buying 325 shares at roughly $79 each. GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions. GE Healthcare is one of the global leaders in Precision Diagnostics with an industry-leading injectable pharmaceutical portfolio in contrast media and molecular imaging. GE Healthcare is one of a few companies that offer a full suite of products and solutions to support patients. GEHC YTD mountain GE Healthcare YTD performance Analysts see GE Healthcare growing EPS to $4.33 in 2024, about a 15% increase from this year's outlook.

Search resuls for: "Vizamyl"

12 mentions found